## Tiziano Bandiera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3590824/publications.pdf

Version: 2024-02-01

18	554	13	18
papers	citations	h-index	g-index
18	18	18	1080 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Graphene Oxide Nanosheets Disrupt Lipid Composition, Ca <sup>2+</sup> Homeostasis, and Synaptic Transmission in Primary Cortical Neurons. ACS Nano, 2016, 10, 7154-7171.	14.6	124
2	Antimicrobial, antioxidant, and waterproof RTV silicone-ethyl cellulose composites containing clove essential oil. Carbohydrate Polymers, 2018, 192, 150-158.	10.2	56
3	Graphene Oxide Upregulates the Homeostatic Functions of Primary Astrocytes and Modulates Astrocyte-to-Neuron Communication. Nano Letters, 2018, 18, 5827-5838.	9.1	47
4	Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. International Journal of Molecular Sciences, 2021, 22, 5262.	4.1	45
5	An Increase in Membrane Cholesterol by Graphene Oxide Disrupts Calcium Homeostasis in Primary Astrocytes. Small, 2019, 15, e1900147.	10.0	37
6	Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Science Advances, 2020, 6, eaay9669.	10.3	34
7	PET nanoplastics interactions with water contaminants and their impact on human cells. Environmental Pollution, 2021, 271, 116262.	7.5	33
8	Antiangiogenic Effect of Graphene Oxide in Primary Human Endothelial Cells. ACS Applied Materials & Amp; Interfaces, 2020, 12, 22507-22518.	8.0	29
9	Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of ⟨i⟩O⟨li⟩-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase. Journal of Medicinal Chemistry, 2017, 60, 2287-2304.	6.4	28
10	Synthesis and Structure–Activity Relationship Studies of <i>O</i> Peripherally Restricted Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 5917-5930.	6.4	24
11	Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase. Chemical Communications, 2014, 50, 4904-4907.	4.1	23
12	Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta. JCI Insight, 2020, 5, .	5.0	21
13	The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. International Journal of Molecular Sciences. 2022, 23, 3175.	4.1	19
14	Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1 <i>H</i> -pyrido[4,3- <i>b</i> )indoles as a Novel Class of CFTR Potentiators. Journal of Medicinal Chemistry, 2020, 63, 11169-11194.	6.4	12
15	Same analytical method for both (bio)assay and zone isolation to identify/quantify bioactive compounds by quantitative nuclear magnetic resonance spectroscopy. Journal of Chromatography A, 2020, 1628, 461434.	3.7	10
16	Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation. ChemMedChem, 2020, 15, 949-954.	3.2	4
17	CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium. Cells, 2022, 11, 1938.	4.1	4
18	Green chemistry and first-principles theory enhance catalysis: synthesis and 6-fold catalytic activity increase of sub-5 nm Pd and Pt@Pd nanocubes. Nanoscale, 2022, 14, 10155-10168.	5.6	4